Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Henry Brown"'
Autor:
Agostina Nardone, Rachel Schiff, Henry Brown, Meghana V. Trivedi, Martin Shea, Mark Pilling, Jamunarani Veeraraghavan, Chandandeep Nagi, Rinath Jeselsohn, Carmine De Angelis, Oona Delpuech, Maria Letizia Cataldo, Tamika Mitchell, C. Kent Osborne, Mothaffar F. Rimawi, Hazel M. Weir, Gary C. Chamness, Xiaoyong Fu, Susan G. Hilsenbeck
Publikováno v:
British Journal of Cancer
BACKGROUND: The oestrogen receptor (ER) is an important therapeutic target in ER-positive (ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but its intramuscular route of admin
Autor:
Catherine Anne Eberlein, Garry Beran, Eiki Ichihara, William Pao, Zhongwu Lai, Henry Brown, Daniel Stetson, Paul R. Fisher, Jonathan R. Dry, Claire Barnes, Ambar Ahmed, Paul D. Smith, Miika Ahdesmaki, Paula J. Spitzler, Catherine B. Meador, Darren Cross, Elizabeth L. Christey O'Brien, Sarah Ross, Katherine Al-Kadhimi, Kenneth S. Thress, Laura E. Ratcliffe, Brian Dougherty, Aleksandra Markovets
Publikováno v:
Cancer Research. 75:2489-2500
Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detectio
Autor:
Lenka Oplustilova, Stephen Green, Henry Brown, Claire Crafter, Cath Trigwell, Sabina Cosulich, Oona Delpuech, Jon Curwen
Publikováno v:
Cancer Research. 75:4719-4719
Two emerging mechanisms of endocrine resistance in estrogen receptor positive (ER+) breast cancers include the activation of the phosphatidylinositol 3-kinase (PI3K) / mammalian target of rapamycin (mTOR) pathway and the de-coupling of cell cycle con
Autor:
Brian Dougherty, Sarah Ross, William Pao, Paul R. Fisher, Darren Cross, Katie Al-Kadhimi, Cath Eberlein, Daniel Stetson, Zhongwu Lai, Henry Brown, Kenneth S. Thress
Publikováno v:
Clinical Cancer Research. 21:PR05-PR05
First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) are established first line therapies for patients with advanced NSCLC with activating/sensitising mutations in EGFR. Unfortunately, patients ultimately develop disease progression wi
Autor:
Kenneth S. Thress, Paul R. Fisher, Darren Cross, Zhongwu Lai, Henry Brown, Brian Dougherty, Katie Al-Khadimi, Lucy O'Brien, William Pao, Claire Barnes, Daniel Stetson, Gayle Marshall, Cath Eberlein, Laura E. Ratcliffe
Publikováno v:
Cancer Research. 74:1722-1722
First- and second-generation EGFR TKIs are established first line therapy for patients with NSCLC with activating mutations in EGFR. Unfortunately, patients ultimately develop disease progression with acquisition of a second-site EGFR T790M mutation
Autor:
Stephen A. Smith, Geoffrey Stemp, Derek N. Middlemiss, Graham J. Riley, Izzy Boyfield, Maureen A.M. Healy, David G. Cooper, Ron J. King, Amanda Johns, Martyn C. Coldwell, Thomas Henry Brown, David John Nash, Jim J. Hagan, Emma E. Scott, Michael S. Hadley
Publikováno v:
Journal of medicinal chemistry. 39(10)
Autor:
Robert John Ife, Leach Colin Andrew, Kenneth Wiggall, Thomas Henry Brown, Michael E. Parsons, Colin J. Theobald, David J. Keeling
Publikováno v:
Journal of medicinal chemistry. 38(14)
3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H + /K + )-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK&F 96067). In the present study the further structure-activity relationship of this seri
Autor:
Thomas Henry Brown, C. Robin Ganellin, Graham J. Durant, Terence F. Walker, D.Anthony Rawlings, Michael E. Parsons, Robert Blakemore, John Colin Emmett
Publikováno v:
European Journal of Medicinal Chemistry. 23:53-62
A series of 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-4-pyrimidones was prepared based on cimetidine 1. The model compound 4 has modest H2-antagonist activity as shown by its ability to antagonise histamine-stimulated tachycardia in guinea pi
Publikováno v:
Fundamental and Applied Toxicology. 7:533-546
Triamterene (2,4,7-triamino-6-phenylpteridine), a widely used diuretic/antihypertensive agent with weak antifolate activity, has been found to be positive in several in vitro assays for mutagenicity. The present studies were undertaken to characteriz
Autor:
D. Saunders, I R Smith, R Griffiths, M Jones, N. E. Sore, R. C. Mitchell, K K Rana, Rodney C. Young, Thomas Henry Brown, Charon Robin Ganellin
Publikováno v:
Journal of Medicinal Chemistry. 31:656-671
A rational approach to the design of centrally acting agents is presented, based initially upon a comparison of the physicochemical properties of three typical histamine H2 receptor antagonists which do not readily cross the blood-brain barrier with